# 2018/19 Financial Performance

Author: Tarun Basra

Sponsor: Paul Traynor

paper N1

## **Executive Summary**

### Context

1.1 The Trust originally planned for an income and expenditure deficit of £29.9m in 2018/19 with a capital plan of £50.4m. The Trust Board approved a revision to the income and expenditure deficit of £21.2m in line with NHS Improvement's revised Control Total. If delivered, this revised Control Total would give the Trust access to provider sustainability fund (PSF) of £21.9m giving a reported surplus of £0.8m.

Delivery of the financial plan in 2018/19 is essential in order to maintain our position as an organisation with good financial control; effectively a pre-requisite to access the extremely limited national capital resource for reconfiguration.

### Questions

1. What is our financial performance for the period ending 31<sup>st</sup> May 2018?

#### **M2** Financial Performance

The Trust has achieved a year to date deficit of £17.1m which is in line to Plan.

Underlying performance is in line with Plan with over-performance in Emergency, Non-Elective and Outpatient activity offset with overspends in both pay (across all staff groups) and non-pay driven by high marginal cost to deliver additional activity.

2. What is our performance against the agency ceiling?

Agency expenditure is below the required level (as per the NHSI agency cap for UHL). The cap essentially mandates a 30% reduction on 2015/16 agency spend. This is very positive news especially given our start point as a relatively low use of agency compared to our acute peer group.

3. What is the performance against the Trust's Cost Improvement Programme?

The Trust's Cost Improvement Programme target is £51.5m. To date, £3.1m has been delivered against a plan of £2.4m representing a £0.7m favourable position to plan.

4. How are we managing unfunded cost pressures this year?

In setting budgets appropriately and in accordance with 2017/18 spend levels, the Trust has little additional (reserve) funding to allocate to CMGs to fund any further cost pressures this year. To ensure that this does not impact negatively on the quality of our services, the Chief Executive is chairing a specific Executive Board meeting (Star Chamber) as necessary to consider any such pressures which potentially cannot be avoided. This will ensure that we have senior oversight and transparency regarding such decisions in 2018/19.

### Input Sought

Note the financial performance at Month 2.

## For Reference

Edit as appropriate:

1. The following objectives were considered when preparing this report:

Safe, high quality, patient centred healthcare Effective, integrated emergency care Consistently meeting national access standards Integrated care in partnership with others Enhanced delivery in research, innovation & ed' A caring, professional, engaged workforce Clinically sustainable services with excellent facilities Financially sustainable NHS organisation Enabled by excellent IM&T	[Yes /No /Not applicable] [ <del>Yes</del> / <del>No</del> /Not applicable]
2. This matter relates to the following governance initiati	ives:
Organisational Risk Register Board Assurance Framework	[Yes / <del>No</del> / <del>Not applicable</del> ] [Yes / <del>No</del> / <del>Not applicable</del> ]
3.Related Patient and Public Involvement actions taken,	or to be taken: <b>Considered but not</b> <b>applicable</b>
4.Results of any Equality Impact Assessment, relating to	this matter: Considered but not applicable
5.Scheduled date for the next paper on this topic:	2 <sup>nd</sup> August 2018 TB
6. Executive Summaries should not exceed 2 pages.	[My paper does/ <del>does not</del> comply]
7. Papers should not exceed 7 pages.	[My paper <del>does</del> /does not comply]

# Contents

Executive Summary	Page 2
<ul><li>I&amp;E: Overall Position</li><li>May 2018: Key Facts</li></ul>	Page 3
Financial Performance	Page 4
I&E Bridge	Page 5
Patient Income	
NHS Patient Income	Page 6
Activity & Income: Performance versus Contract	Page 7
Patient Income Run Rates	Page 8
Patient Income Run Rates: Point of Delivery	Page 9
Pay Costs	
Pay Costs	Page 10
Pay Cost Run Rates	Page 11
I&E: Other	
Non-Pay	Page 12
• CIP	Page 13
Financial Improvement and Technical	Page 14
I&E Run Rates	Page 15
Assets & Liabilities	
May 2018: Statement of Financial Position	Page 16
• Cash	Page 17
• Liquidity	Page 18
Better Payments Practice Code	Page 19
Capital	Slide 20

# **Executive Summary**

### **Financial performance**

#### **Statutory duties**

- Delivering the planned deficit: On track
- Achieving the External Funding Limit: On track
- Achieving the Capital Resource Limit: On track

#### **Financial Performance**

- **Deficit of £17.1m, in line with Plan:** Underlying performance is in line with Plan with over-performance in Patient Activity absorbing marginal cost to deliver.
- Patient Care Income, £2.1mF to Plan : Over-performance is predominantly within Emergency and Outpatients with Inpatients in line with Plan.
- **Operating Costs, £1.8mA to Plan:** with pay £0.1mA to Plan with underlying overspend within the CMGs of £1.1m predominantly in Medical and Nursing. Non-pay overspend of £1.7m driven by additional cost to deliver activity together with cost pressures within the CMGs.
- CIP £0.7mF to Plan
- Finance Improvement and Technical in line to Plan
- Forecast: at this stage of the year the full year forecast is consistent with Plan.
- **2018/19 Plan:** following the resubmission of the 2018/19 Annual Operating Plan, as of month three the Finance Report will be updated monitor performance against the revised deficit of £21.1m.


### Cash

- Closing cash balance at May of £6.2m including Trust Med Pharmacy.
- Trust Med Pharmacy cash balance was £0.8m.
- Cash funding to support the operating deficit is in line with plan.

### Capital

- **May**: Total capital expenditure of £3.0m, £0.2mA to Plan driven by IM&T, offset by underspend on Emergency Floor.
- The overspend in Month 2 does not represent a risk to achieving the CRL.

## May 2018: Key Facts



Key

EBITDA refers to Earnings Before Interest, Taxes, Depreciation and Amortisation

Colour indicates status of variance on planned position (Green is Favourable/In Line and Red is Adverse)

Number relates to variance YTD

## Financial Performance: YTD Deficit of £17.1m, in line with Plan

			May-18			YT	)	
		Plan	Actual	Vs Plan	Plan	Actual	F/(A)	
								%
	Day Case	9,201	9,112	(89)	17,869	17,346	(523)	(3%)
	Elective Inpatient	1,784	1,788	4	3,369	3,351	(18)	(1%)
	Emergency / Non-elective Inpatient	10,024	10,620	596	19,692	20,503	811	4%
ers	Emergency Department	20,238	20,617	379	39,823	40,017	194	0%
Value Drivers	Outpatient Procedures	80,851	83,694	2,843	157,988	160,454	2,465	2%
l ne l	Critical Care Services	4,801	4,550	(251)	9,505	9,295	(210)	(2%)
Va	Renal Dialysis and Transplant	15,027	15,168	141	29,536	29,439	(97)	(0%)
	Other Activity	707,375	797,407	90,032	1,381,059	1,440,069	59,010	4%
	WTE Total	14,253	14,165	89	14,253	14,165	89	1%
	WTE Agency	176	173	3	177	173	4	2%
			May-18			YTI	כ	
		Plan £'000	Actual £'000	Vs Plan £'000	Plan £'000	Actual £'000	F/(A) £'000	%
	Patient Care Income	69,222	70,644	1,422	134,901	136,978	2,077	2%
	Non Patient Care Income	594	272	(322)	1,178	809	(369)	(31%)
	Other Operating Income	10,108	9,724	(383)	20,125	20,143	18	0%
	Total Income	79,924	80,640	716	156,204	157,930	1,726	1%
	Pay Costs	(51,228)	(51,308)	(79)	(102,281)	(102,430)	(148)	(0%)
0	Pay Costs: Agency	(1,809)	(1,774)	35	(3,681)	(3,606)	74	2%
I&E £'000	Non Pay	(30,950)	(31,811)	(861)	(60,899)	(62,583)	(1,684)	(3%)
I&E	Total Operating Costs	(83,987)	(84,892)	(905)	(166,861)	(168,619)	(1,758)	(1%)
	EBITDA	(4,063)	(4,252)	(189)	(10,657)	(10,689)	(32)	0%
	Non Operating Costs	(3,254)	(3,075)	179	(6,495)	(6,488)	7	0%
	Retained deficit	(7,317)	(7,327)	(10)	(17,152)	(17,177)	(25)	(0%)
	Adjustments for Donated Assets	16	41	25	32	84	52	163%
	Net Deficit	(7,301)	(7,286)	15	(17,120)	(17,093)	27	0%
Š	Agency: Total Pay	3.53%	3.46%		3.60%	3.52%		
Ratios	EBITDA: Income	(5.08%)	(5.27%)		(6.82%)	(6.77%)		
æ	Net Deficit: Income	(9.13%)	(9.04%)		(10.96%)	(10.82%)		

alue Drive

&E £'000

Kev

- EBITDA refers to Earnings Before Interest, Taxes, Depreciation and Amortisation
- F refers to a Favourable variance to plan
  A refers to an Adverse variance to plan

- NHS Patient Care Income: £137m, £2.1mF including £0.8mA in relation to drugs and devices excluded from tariff with the offset in non-pay. Underlying over-performance of £3.0m predominantly within Emergency and Outpatients with Elective procedures delivered in line with Plan.
- Non Patient Care Income & Other Income: £20.9m, £0.3mA driven by Trust Med Pharmacy (TMP) with the offset in non-pay.
- Pay Costs: £106m in line with Plan with overspend in Medical and Nursing in all CMGs offset by underspend in non-clinical pay costs.

Agency pay remains under the Agency expenditure ceiling.

Pay remains an area of concern to ensure appropriate control and optimum use of financial resources to support the Trust's financial commitments.


 Non-Pay: £62.6m, £1.7mA including £0.8mF relating to drugs and devices excluded from tariff and £0.3mF in relation to TMP income. Underlying overspend is predominantly driven by additional cost to deliver additional activity.

Non-pay pressures need to be continuously controlled in order to maximise the opportunity from over-delivery of activity.

- EBITDA: deficit of £10.7m, in line with Plan.
- Non-Operating Costs: £6.5m, in line with Plan.

### **I&E Bridge: In line with Plan**


Underlying performance is in line with Plan with over-performance within Emergency and Outpatients with Inpatients in line with plan. This over performance is offset by the marginal cost to deliver activity together with cost pressures.



£(000)	Plan	Activity	Theatres	Medical Pay	Nursing Pay	Other Pay	Cost Pressures	Other	Actual	Var F/(A)
NHS PCI	134,901	3,160						(1,083)	136,978	2,077
Other Income	21,253							(299)	20,954	(299)
Pay	(102,281)		(428)	(320)	(1,486)	2,085		0	(102,430)	(148)
Pay: Agency	(3,681)			(849)	857	66		0	(3,606)	74
Non Pay	(60,899)	(2,108)	(199)				(494)	1,118	(62,583)	(1,684)
Non-Operating Costs	(6,413)							7	(6,406)	7
Net Deficit	(17,120)	1,052	(627)	(1,169)	(629)	2,151	(494)	(258)	(17,093)	27

# NHS Patient Income: May £136.9m, £2.1mF to Plan

Over-performance predominantly driven by Emergency/Non-elective within Cardiology, Integrated Medicine, Rehabilitation and Hepatology and Outpatients.



£(m)	Plan	Rate	Volume	Other	Actual	Var F / (A)
Day Case	9,949	81	(293)	0	9,737	(212)
Elective Inpatient	12,078	228	(65)	0	12,241	163
Emergency / Non-elective Inpatient	36,988	756	1,554	0	39,299	2,311
Marginal Rate Emergency Threshold	(1,023)	0	0	(735)	(1,757)	(735)
Emergency Department	5,373	(173)	25	0	5,226	(147)
Outpatient	18,606	258	294	0	19,159	553
Drugs and Devices excluded from Tariff	17,344	0	0	(845)	16,500	(845)
Critical Care Services	8,910	382	(205)	0	9,087	177
Renal Dialysis and Transplant	4,664	3	(15)	0	4,652	(12)
CQUIN	2,740	0	0	96	2,836	96
Other Activity	17,850	0	0	256	18,106	256
Other Financial Values	1,420	0	0	473	1,893	473
Total	134,900	1,535	1,296	(754)	136,977	2,077

# **Activity & Income: Performance versus Contract**

Case Mix	City	East	West	Specialised	Other	Alliance	Total	%
Day Case	(331)	35	(144)	242	(203)	(121)	(523)	(3%)
Elective Inpatient	(14)	(4)	(56)	23	34		(18)	(1%)
Emergency / Non-elective Inpatient	301	91	274	132	14		811	4%
Marginal Rate Emergency Threshold (MRET)	0	0	0	0	0		0	0%
Emergency Department	(9)	19	281		(97)		194	0%
Outpatient	811	922	1,577	470	(944)	(370)	2,465	2%
Excluded Drugs and Devices					0	0	0	0%
Critical Care Services	293	(173)	96	(407)	(19)		(210)	(2%)
Renal Dialysis and Transplant	0	0	0	(96)	(2)		(97)	(0%)
CQUIN	0	0	0	0	0	0	0	0%
Other Activity	1,397	49,790	14,639	(276)	(5,849)	(517)	59,184	4%
Other Financial Values	327	423	392	101	626	149	2,017	0%

Activity

Case Mix	City (£000)	East (£000)	West (£000)	Specialised (£000)	Other (£000)	Alliance (£000)	Total (£000)	%
Day Case	(164)	91	66	194	(268)	(131)	(212)	(2%)
Elective Inpatient	119	93	(152)	(126)	229	0	163	1%
Emergency / Non-elective Inpatient	774	154	894	399	89	0	2,311	6%
Marginal Rate Emergency Threshold (MRET)	(217)	(145)	(251)	0	(121)	0	(735)	(72%)
Emergency Department	(37)	(23)	17	0	(104)	0	(147)	(3%)
Outpatient	214	175	277	29	(97)	(45)	553	3%
Excluded Drugs and Devices	(145)	(147)	(88)	(241)	(225)	0	(845)	(5%)
Critical Care Services	484	(164)	37	(269)	89	0	177	2%
Renal Dialysis and Transplant	0	0	0	(12)	(0)	0	(12)	(0%)
CQUIN	37	13	26	21	3	(5)	96	3%
Other Activity	(25)	263	103	15	(67)	(34)	256	1%
Other Financial Values	190	179	186	(173)	112	(18)	474	33%
Grand Total	1,232	488	1,115	(163)	(360)	(233)	2,078	2%


#### **Contracts:**

- LLR contracts: £2.8m over-performance by primarily Emergency admissions and outpatients
- Specialised Services: in line with Plan

#### Point of Delivery:

- Day Case & Elective Inpatient: Majority of the under-performance is occurring within Paediatric Cardiothoracic Surgery and General Surgery. However some of the under-performance is being offset with over-performance within Orthopaedic Surgery, Podiatric Surgery and Spinal Surgery.
- Emergency / Non Elective: Over performance across a wide range of specialties with Integrated Medicine, Cardiology, Rehabilitation and Hepatology having the most of the over-performance. Offset by underperformance in Gastroenterology and Geriatric Medicine.
- **Outpatients:** The majority of the overperformance is occurring within Follow-up appointments. There are a range of Specialties which are over performing with Integrated Medicine, Haematology and Dermatology over-performing the most.
- Excluded Drugs and Devices: Underperformance within Rheumatology, Infectious Diseases and New Hep C therapies offset partially offset by over performance in Clinical Oncology, and Gastroenterology.
- Alliance: Driven by Day Case within Orthopaedic Surgery and Ophthalmology and Outpatients within Dermatology and Orthopaedic Surgery.


### **Patient Income Run Rates**



#### Year to Date

- Year to date over-performance of £2.1m which includes £0.8mA in relation to drugs and devices excluded from tariff.
- Over-performance predominantly driven by Emergency and Outpatients within a wide range of specialties including Cardiology, Geriatric Medicine and General Surgery.

## **Patient Income Run Rates: Point of Delivery**



# Pay: YTD £106.0m, £0.1mA to Plan

				May-	18					YTI	)		
			£'000			WTE			£'000			WTE	
		Plan	Actual	F/(A)	Plan	Actual	F/(A)	Plan	Actual	F/(A)	Plan	Actual	F/(A)
	Medical	624	1,031	(407)	3	47	(44)	1,300	2,148	(849)	3	47	(44)
~	Nursing & Midwifery	919	445	475	11	97	(86)	1,844	987	857	11	97	(86)
Agency	Other Clinical	211	255	(44)	35	18	17	427	380	47	35	18	17
Ag	Non Clinical	55	44	11	15	11	4	110	91	19	15	11	4
	Total:Agency	1,809	1,774	35	64	173	(109)	3,681	3,606	74	64	173	(109)
	Medical	0	1,403	(1,403)	0	6	(6)	0	2,877	(2,877)	0	6	(6)
on- ted	Nursing & Midwifery	0	1,677	(1,677)	0	491	(491)	0	3,484	(3,484)	0	491	(491)
er N	Other Clinical	0	332	(332)	0	69	(69)	0	680	(680)	0	69	(69)
Other Non- contracted	Non Clinical	0	516	(516)	0	271	(271)	0	1,107	(1,107)	0	271	(271)
00	Total: Other Non-contracted	0	3,928	(3,928)	0	835	(835)	0	8,147	(8,147)	0	835	(835)
	Medical	624	2,434	(1,810)	3	53	(50)	1,300	5,025	(3,726)	3	53	(50)
ed 'n	Nursing & Midwifery	919	2,434	(1,202)	11	587	(577)	1,300	4,471	(2,627)	11	587	(577)
l No ract	Other Clinical	211	587	(376)	35	87	(52)	427	1,060	(633)	35	87	(577)
Total Non- contracted	Non Clinical	55	560	(505)	15	282	(266)	110	1,198	(1,087)	15	282	(266)
μõ	Total: Non-contracted	1,809	5,702	(3,894)	64	1,008	(945)	3,681	11,754	(8,073)	64	1,008	(945)
	·				1 000			,	,		4 000	,	
ě	Medical	15,658	14,744	913	1,882	1,818	64	31,375	29,062	2,313	1,882	1,818	64
anti	Nursing & Midwifery	17,317	16,488	829	5,898	5,432	467	34,217	32,289	1,927	5,898	5,432	467
Substantive	Other Clinical	8,090	6,641	1,449	2,286	2,110	177	16,389	13,298	3,091	2,286	2,110	177
Su	Non Clinical	10,164	9,506	657 <b>3,849</b>	4,123	3,969	153 861	20,300	19,633	667	4,123	3,969	153 861
	Total: Substantive	51,228	47,379	3,849	14,190	13,329	861	102,281	94,283	7,999	14,190	13,329	861
	Medical	16,281	17,178	(897)	1,886	1,871	14	32,674	34,087	(1,412)	1,886	1,871	14
=	Nursing & Midwifery	18,236	18,609	(373)	5,909	6,019	(110)	36,060	36,760	(700)	5,909	6,019	(110)
Total	Other Clinical	8,301	7,228	1,073	2,321	2,196	125	16,817	14,359	2,458	2,321	2,196	125
-	Non Clinical	10,219	10,067	152	4,138	4,251	(113)	20,411	20,831	(420)	4,138	4,251	(113)
	TOTAL: Pay	53,037	53,081	(44)	14,253	14,338	(84)	105,962	106,036	(74)	14,253	14,338	(84)

#### **Agency Pay**

• Year to date cost of £3.6m, in line with Plan. Medical overspend offset by nursing underspend predominantly within ESM.

#### **Other Non-contracted Pay**

- Other non-contracted pay consists of overtime, bank, WLIs and internal locums.
- Year to date expenditure of £8.2m with Medical and Nursing driving 78% of spend. Whilst premium pay shows an overspend this needs to be taken into account with Substantive Pay as budgets are held at Established levels.


#### **Substantive Pay**

- Combined with other non-contracted, expenditure of £102.4m, £0.1mA to Plan including £2.4m overspend in the CMGs driven by:
  - Medical: £0.8mA across most CMGs;
  - Nursing: £1.7mA across most CMGs;
- Lack of control of pay costs is a key risk with the plan requiring a reduction in the 2017/18 exit run rate representing delivery of CIP and underlying reduction in WTEs.

Note

Other non-contracted medical pay is not represented by a WTE value as it represents an aggregate of payments like Waiting List Initiatives (WLI), on call, acting down payments across different grades of medical workforce where individuals often already represent 1 WTE in a substantive, contracted, role.

## **Pay Run Rates**



#### **Total Pay excluding Agency Pay**

• This remains a key risk to the Financial Plan as we exit 2017/18 especially in relation to ED Floor, staff enhancements in excess of Agenda for Change and NHSI rates together with unfunded cost pressures.

#### **Agency Pay**

- The planned trajectory is supported by specific actions identified and tracked through the Premium Pay group.
- The NHSI Agency Ceiling for 2018/19 is £18.8m.

# Non-Pay: YTD £62.6m, £1.7mA to Plan

Drugs 9,494 8,401 1,093 12% 18,469 17,012 1,457 Clinical Supplies & Services 9,131 10,012 (881) (10%) 17,733 18,854 (11,120) (6 Transport 321 305 16 5% 630 681 (51) (8 Recharges 197 371 (175) (89%) 391 717 (326) (84 Misc & General Supplies 3,031 3,403 (372) (12%) 6,107 7,633 (11,526) (25 Healthcare 916 838 79 9% 1,840 1,725 116 4 Non Healthcare 1,223 1,275 (52) (4%) 2,446 2,579 (133) (5 Establishment, Premises & Plant 3,805 4,314 (509) (13%) 7,621 7,712 (91) (1 Consultancy 42 73 (31) (74%) 85 71 13 1 Clinical Negligence 2,661 2,661 (0) (0%) 5,321 5,321 (0) (0 it Non Pay 30,950 31,811 (861) (3%) 60,899 62,583 (1,684) (3 Plan 5000 Plan 5000					Ma	y-18			ΥT	D	
Drugs 9,494 8,401 1,093 12% 18,469 17,012 1,457 5 Clinical Supplies & Services 9,131 10,012 (881) (10%) 17,733 18,854 (1,120) (6 Transport 321 305 16 5% 630 681 (51) (8 Recharges 197 371 (175) (89%) 391 717 (326) (84 Misc & General Supplies 3,031 3,403 (372) (12%) 6,107 7,633 (1,526) (25 Healthcare 916 838 79 9% 1,840 1,725 116 9 Non Healthcare 1,223 1,275 (52) (4%) 2,446 2,579 (133) (5 Establishment, Premises & Plant 3,805 4,314 (509) (13%) 7,621 7,712 (91) (1 Consultancy 42 73 (31) (74%) 85 71 13 10 Clinical Negligence 2,661 2,661 (0) (0%) 5,321 5,321 (0) (0 It Non Pay 30,950 31,811 (861) (3%) 60,899 62,583 (1,684) (3 Plan 5000 Plan 5000									Actual	F / (/	
Clinical Supplies & Services       9,131       10,012       (881)       (10%)       17,733       18,854       (1,120)       (6         Transport       321       305       16       5%       630       681       (51)       (8         Recharges       197       371       (175)       (89%)       391       717       (326)       (84         Misc & General Supplies       3,031       3,403       (372)       (12%)       6,107       7,633       (1,526)       (25         Healthcare       916       838       79       9%       1,840       1,725       116       16         Non Healthcare       1,223       1,275       (52)       (4%)       2,446       2,579       (133)       (5         Establishment, Premises & Plant       3,805       4,314       (509)       (13%)       7,621       7,712       (91)       (1         Consultancy       42       73       (31)       (74%)       85       71       13       1         Clinical Negligence       2,661       2,661       (0)       (0%)       5,321       5,321       (0)       (0         It Non Pay       566       667       667       667       667		Blood Produc	ts	130	158	(29)	(22%)	255	277	(22)	(9%
Body Port       Loca		Drugs		9,494	8,401	1,093	12%	18,469	17,012	1,457	8
Body Port       Loca	Direct	Clinical Suppl	lies & Services	9,131	10,012	(881)	(10%)	17,733	18,854	(1,120)	(69
Misc & General Supplies       3,031       3,403       (372)       (12%)       6,107       7,633       (1,526)       (25         Healthcare       916       838       79       9%       1,840       1,725       116	Dir	Transport		321	305	16	5%	630	681	(51)	(89
Healthcare       916       838       79       9%       1,840       1,725       116         Non Healthcare       1,223       1,275       (52)       (4%)       2,446       2,579       (133)       (5         Establishment, Premises & Plant       3,805       4,314       (509)       (13%)       7,621       7,712       (91)       (1         Consultancy       42       73       (31)       (74%)       85       71       13       1         Clinical Negligence       2,661       2,661       (0)       (0%)       5,321       5,321       (0)       (0)         It: Non Pay       30,950       31,811       (861)       (3%)       60,899       62,583       (1,684)       (3)         Fig       900       1,692       60,899       62,583       (1,684)       (3)         It: Non Pay       30,950       31,811       (861)       (3%)       60,899       62,583       (1,684)       (3)         It: Non-Pay       9000       1000       1000       1000       1000       1000       1000       1000       1000       1000       1000       1000       1000       1000       1000       1000       1000       1000 <td< td=""><td></td><td>Recharges</td><td></td><td>197</td><td>371</td><td>(175)</td><td>(89%)</td><td>391</td><td>717</td><td>(326)</td><td>(84</td></td<>		Recharges		197	371	(175)	(89%)	391	717	(326)	(84
Establishment, Premises & Plant 3,805 4,314 (509) (13%) 7,621 7,712 (91) (1 Consultancy 42 73 (31) (74%) 85 71 13 1 Clinical Negligence 2,661 2,661 (0) (0%) 5,321 5,321 (0) (0 1: Non Pay 30,950 31,811 (861) (3%) 60,899 62,583 (1,684) (3 Plan 5,39,079 Non-Pay 5,000 339,079 Non-Pay 5,000 1		Misc & Gene	ral Supplies	3,031	3,403	(372)	(12%)	6,107	7,633	(1,526)	(25
Establishment, Premises & Plant 3,805 4,314 (509) (13%) 7,621 7,712 (91) (1 Consultancy 42 73 (31) (74%) 85 71 13 1 Clinical Negligence 2,661 2,661 (0) (0%) 5,321 5,321 (0) (0 1: Non Pay 30,950 31,811 (861) (3%) 60,899 62,583 (1,684) (3 Plan 5,39,079 Non-Pay 5,000 339,079 Non-Pay 5,000 1	External Providers	Healthcare		916	838	79	9%	1,840	1,725	116	e
Li Non Pay 30,950 31,811 (861) (3%) 60,899 62,583 (1,684) (3 Plan 339,079 Non-Pay	Exte Prov	Non Healthca	are	1,223	1,275	(52)	(4%)	2,446	2,579	(133)	(5
Li Non Pay 30,950 31,811 (861) (3%) 60,899 62,583 (1,684) (3 Plan 339,079 Non-Pay	ads	Establishmen	nt, Premises & Pl	ant 3,805	4,314	(509)	(13%)	7,621	7,712	(91)	(1
Li Non Pay 30,950 31,811 (861) (3%) 60,899 62,583 (1,684) (3 Plan 339,079 Non-Pay	Overheads	Consultancy		42	73	(31)	(74%)	85	71	13	16
66667 Plan 339,079 Post of the second seco	õ	Clinical Negli	igence	2,661	2,661	(0)	(0%)	5,321	5,321	(0)	(0
Plan 339,079	otal: Non	n Pay		30,950	31,811	(861)	(3%)	60,899	62,583	(1,684)	(39
Beecco 20,050 1,00,00 1,00,								Plan	1		
29,949 30,757					Non-Pa	ay			-		
	29,949	31,02		28,562	27,587	27,851	27,671	26,622	27,716	26,179	26,847
Apr-18 May-18 Jun-18 Jul-18 Aug-18 Sep-18 Oct-18 Nov-18 Dec-18 Jan-19 Feb-19	-									2(	

Plan

Actual

— Actual RR


• Direct Costs: £45.2m, £1.6mA to Plan including £0.8mF in relation to drugs and devices excluded from tariff.

Underlying overspend driven by additional cost to deliver activity together with cost pressures within the CMGs.

- **External Providers:** YTD cost of £4.3m which in line with Plan.
- **Overheads:** YTD expenditure of £13.1m, £0.1mA to Plan predominantly within Estates.
- Non-pay remains a critical area of spend to ensure tight cost control underpinned by activity performance.

# CIP: YTD £3.1m, £0.7mF to Plan

		May-	18			YTD			
	Plan £'000	Actual £'000	F / (A £'000	() %	Plan £'000	Actual £'000	F / (A) £'000	) %	FY Plan £'000
CHUGGS	91	224	133	145%	182	322	140	77%	3,467
CSI	221	245	24	11%	425	454	29	7%	2,287
ESM	200	81	(119)	(59%)	399	731	332	83%	5,189
ITAPS	83	85	2	3%	150	146	(4)	(3%)	2,908
MSS	287	252	(35)	(12%)	491	430	(61)	(12%)	3,912
RRCV	311	435	124	40%	608	733	125	21%	5,253
Womens & Childrens	55	62	8	14%	108	116	8	7%	5,268
Total: CMG	1,248	1,385	137	11%	2,363	2,932	569	24%	28,283
Facilities & Estates	61	121	60	98%	122	189	66	54%	2,377
Corporate Total	3	16	13	525%	5	22	17	342%	1,394
Central	0	0	0	0%	0	0	0	0%	19,426
Total CIP	1,312	1,522	210	16%	2,491	3,143	652	26%	51,480



- Month 2 delivery favourable to plan driven by:
  - CHUGGS driven by Patient Care
     Income in surgery and pay costs
  - ESM over performance in Emergency;
  - RRCV driven by Day Case Patient Care within Cardiology

The Financial benefit of the schemes is being offset by cost pressures within the CMGs

- Theatres demand and capacity to be included in the revised plan from month 3.
- Quality Impact Assessment reviews with the chief nurse and medical director are set to be completed by 30<sup>th</sup> June for all schemes which are reported as delivering in quarter 1.
- The programme will have identified 100% of the plan by 30<sup>th</sup> June 2018.


# **Finance Improvement and Technical (FIT)**

on-CIP £'000 250	Total £'000 3,900	Plan £'000	Actual £'000	Variance £'000
		£'000	£'000	£'000
250	3,900			
250		0	0	0
250	4,000	0	0	0
200	250	0	0	0
250	8,150	0	0	0
150	150	0	0	0
2,456	2,456	205	205	0
	150	0	0	0
2,606	2,756	205	205	0
2,268	7,944	0	0	0
	5,700	0	0	0
2,268	13,644	0	0	0
			_	_
250	8,150	0	0	-
2,606	2,756	205	205	0
2,268	13,644	0	0	0
	24,550	205	205	0
		2,268 13,644	2,268 13,644 0	2,268 13,644 0 0


205 Jul-Mar-Apr-May-Sep-Oct-Nov-Dec-Feb-Jun-Aug-Jan-


- 2018/19 Plan identified £24.6m of Finance Improvement and Technical actions in order to help meet the planned deficit.
- Month 2 is in line to plan with the impact of actions predominantly planned to be delivered from October underpinned by launch of FM LLP and the sale of the Paddock.

### **I&E Run Rates**



**Total Pay** 









Plan Actual YTD RR

Non-Op Costs





Plan Actual -YTD RR

# **May 2018: Statement of Financial Position**

	Mar-18 £000's Actual	May-18 £000's Actual	Movement £000's Actual
Property, plant and equipment	427,610	426,816	(794)
Intangible assets	11,480	11,069	(411)
Trade and other receivables	2,904	2,978	74
Total Non Current Assets	441,994	440,864	(1,130)
Inventories	23,829	23,700	(129)
Trade and other receivables	70,519	65,737	(4,782)
Other Financial assets	0	0	0
Cash and cash equivalents	2,900	6,245	3,345
Total Current Assets	97,248	95,682	(1,566)
Trade and other payables	(112,706)	(117,901)	(5,195)
Dividend payable	0	(1,065)	(1,065)
Borrowings / Finance Leases	(4,518)	(4,518)	0
Other Liabilities / Loan	(36,260)	(36,260)	(0)
Provisions for liabilities and charges	(448)	(448)	0
Total Current Liabilities	(153,932)	(160,192)	(6,260)
Net Current Liabilities	(56,684)	(64,511)	(7,827)
Total Assets less Net Current Liabilities	385,310	376,353	(8,957)
Borrowings / Finance Leases	(6,395)	(6,396)	(1)
Other Liabilities / Loan	(162,075)	(170,475)	(8,400)
Provisions for liabilities and charges	(1,465)	(1,284)	181
Total Non Current Liabilities	(169,935)	(178,154)	(8,219)
Total Assets Employed	215,375	198,199	(17,176)
Public dividend capital	331,956	331,956	(0)
Revaluation reserve	98,349	98,349	(0)
Retained earnings	(214,930)	(232,106)	(17,176)
Total Taxpayers Equity	215,375	198,199	(17,176)

- **Total Assets Employed:** Movement of £17.2m representing year to date Trust deficit.
- Non-Current Assets : Increased by £1.1m.


#### • Working capital:

- Trade receivables have increased by £4.8m
- Trade payables have increased by £5.1m
- **Cash:** May balance of £6.2m is above the £1m target cash balance due to the timing of cash receipts, and includes TMP cash.

#### • Non-current liabilities:

- Increase due to loan funding received in May.
- Liquidity Ratio: We continue to be high risk in terms of our continuity of service risk rating relating to liquidity days and have achieved a score of 4 (high risk), which is in line with our plan.

### May 2018 Cash movement



#### Cash Bridge:


- Opening cash balance of £3.4m, in line with our plan.
- Funded YTD operating deficit (net of PDC) of £16m and movement in working capital by securing £3.1m of external financing.

#### **Full Year Forecast**

• Forecast of £1m cash holding at the year end.

#### **Daily Cash Balance**

 In line with forecast the mid-month peak is driven by receipt of SLA income and reduction on 25<sup>th</sup> May due to the monthly payroll run.



# Liquidity

		Opening	YTD	Movement	0 - 30 Days	31 - 60 Days	61 - 90 Days	Over 90 Days	Over 90 Days
		£'000	£'000	£'000	£'000	£'000	£'000	£'000	%
Accounts Receivable	NHS receivables - revenue	36,268	20,966	15,302	7,421	2,590	1,052	9,903	47%
	Non-NHS receivables - revenue	23,444	28,787	(5,343)	20,708	1,026	1,212	5,841	20%
	Provision for the impairment of receivables	0	0	0	0				
	Non-NHS prepayments and accrued income	7,271	12,417	(5,146)	12,417				
	PDC dividend prepaid to DH	0	0	0	0				
	VAT	2,011	2,301	(290)	2,301				
	Other receivables	1,525	1,266	259	1,266				
	TOTAL	70,518	65,737	4,781	44,113	3,616	2,264	15,744	
	NHS payables - revenue	(35,065)	(34,194)	(871)	(15,254)	(1,665)	(1,696)	(15,579)	46%
	NHS accruals and deferred income	0	0	0	0				
e	Non-NHS payables - revenue	(33,650)	(34,796)	1,146	(21,790)	(7,670)	(3,608)	(1,728)	5%
Accounts Payable	Non-NHS payables - capital	(4,307)	(856)	(3,451)	919	(1,090)	(648)	(37)	4%
	Non-NHS accruals and deferred income	(10,699)	(18,752)	8,053	(11,743)	(4,133)	(1,944)	(931)	5%
unts	Social security costs	(6,969)	(6,736)	(234)	(6,736)				
1000	Accrued Interest on DH Loans		0		0				
Ā	Tax	(5,892)	(5,873)	(19)	(5,873)				
	Other	(12,649)	(11,965)	(683)	(11,965)				
	TOTAL	(109,231)	(113,172)	3,941	(72,442)	(14,558)	(7,896)	(18,275)	
Total Liquidity		(38,713)	(47,435)	8,722					

Liquidity: movement of £8.7m from opening position due to:

- Accounts receivable: decrease of £4.8m.
- Accounts payable: increase of £3.9m due to the receipt of working capital loans.

**Ageing:** NHSI target of 5% or less within over 90 days, key areas of under-performance:

- NHS receivables: 47% representing £9.9m being over 90 days.
- Non-NHS receivables: 20% representing £5.8m being over 90 days with the largest component being Overseas Visitors at £2.5m. This balance consists of various items which in isolation are not material.
- NHS payables-revenue: £15.6m, representing 46% over 90 days; non-NHS payables 5% (£1.7m) over 90 days; non-NHS accruals and deferred income 5% (£0.9m) over 90 days.
- Further analysis of receivables is provided in the separate cash report.

# **Better Payments Practice Code: Non-compliant**

Better Payment Practice Code -	Мау Ү	TD	Prior month YTD		
Measure of Compliance	Number	£000s	Number	£000s	
All					
Total Invoices Paid in the Year	29,266	122,430	14,782	60,951	
Total Invoices Paid Within Target	12,552	82,841	6,696	44,755	
Percentage Invoices Paid Within Target (target 95%)	43%	68%	45%	73%	
Non-NHS Payables					
Total Non-NHS Invoices Paid in the Year	28,057	99,835	14,411	49,792	
Total Non-NHS Invoices Paid Within Target	12,324	69,742	6,579	36,799	
Percentage of Non-NHS Invoices Paid Within Target	44%	70%	46%	74%	
Local SME payables					
Total SME Invoices Paid in the Year	109	1,180	38	460	
Total SME Invoices Paid Within Target	23	175	13	79	
Percentage of Local SME Invoices Paid Within Target	21%	15%	34%	17%	
NHS Payables					
Total NHS Invoices Paid in the Year	1,100	21,416	333	10,700	
Total NHS Invoices Paid Within Target	205	12,924	104	7,877	
Percentage of NHS Invoices Paid Within Target	19%	60%	31%	74%	

#### • BPPC performance:

As a result of cash constraints the Trust is unable to achieve the BPPC performance target of 95%.

The low volume compliance has been driven by the requirement to settle high value invoices, impacting our ability to pay the larger volume of small invoices within 30 days.

# Capital: May £3.0m spend, £0.2mA to Plan

	Annual	Year to Date - May 18			
Scheme Name	Budget	Plan	Actual	F / (A)	
	£'000	£'000	£'000	£'000	
Interim ICU Projects	27,392	200	69	131	
UHL Reconfiguration Programme	1,425	230	76	154	
Donations	300	50	0	50	
Estates & Facilities	6,305	600	99	501	
IM&T Schemes	6,160	350	1,554	(1,204)	
Medical Equipment Schemes	2,591	111	43	68	
Medical Equipment Schemes - CMG	1,625	50	42	8	
EMCHC	2,992	50	8	42	
Other	300	0	84	(84)	
Emergency Floor	1,308	1,208	285	923	
MES	0	0	754	(754)	
Total Capital Expenditure	50,398	2,849	3,014	(165)	